Bronchodilation of formoterol administered with budesonide: Device and formulation effects

Contemporary Clinical Trials

Volumn 29, Issue 2, 2008, Pages 114-124

  Miller, Christopher J ^a   Senn, Stephen ^b   Mezzanotte, William S ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Asthma; Budesonide; Dry powder inhaler; Formoterol; Pressurized metered dose inhaler; Relative dose potency

Indexed keywords

BUDESONIDE; FORMOTEROL;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; FORCED EXPIRATORY VOLUME; HUMAN; METERED DOSE INHALER; MONOTHERAPY; MULTICENTER STUDY; SCREENING; SPIROMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOSAGE FORMS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 39049093630     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2007.05.008     Document Type: Article

References (24)

1. Buhl R., Creemers J.P., Vondra V., et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 97 (2003) 323-330
2. Lalloo U.G., Malolepszy J., Kozma D., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 123 (2003) 1480-1487
3. Tal A., Simon G., Vermeulen J.H., et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 34 (2002) 342-350
4. Zetterström O., Buhl R., Mellem H., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
5. Noonan M., Rosenwasser L., Martin P., O'Brien C.D., and O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler administered to adults and adolescents with moderate to severe persistent asthma. Drugs 66 (2006) 2235-2254
6. Food and Drug Administration. Title 21. Food and drugs chapter I-food and drug administration department of health and human services, subchapter D-drugs for human use, subpart B-combination drugs (21CFR300.50). [Cited 2006 April 19.] Available from http://www.fda.gov.
7. Food and Drug Administration. Reviewer guidance for nebulizers, metered dose inhalers, spacers and actuators (October 1 1993), US Department of Health and Human Services, Rockville, Md
8. Houghton C.M., Langley S.J., Singh S.D., et al. Comparison of bronchoprotective and bronchodilator effects of a singe dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 58 (2004) 359-366
9. Bousquet J., Huchon G., Leclerc V., Vicaut E., and Lefrancois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 72 Suppl 1 (2005) 6-12
10. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
11. Crapo R. Reference values for lung function tests. Respir Care 34 (1989) 626-637
12. Senn S. Cross-over trials in clinical research. In: Barnett, V., series ed. Statistics in practice. New York: John Wiley & Sons; 1993:54-9, 143-55, 199-221.
13. Senn S. Cross-over trials in clinical research. 2nd ed. (2002), John Wiley & Sons, Chichester, England 272-275
14. Källén A., and Larsson P. Dose response studies: how do we make them conclusive?. Stat Med 18 (1999) 629-641
15. Senn S.J., Lillienthal J., Patalano F., and Till D. An incomplete blocks cross-over in asthma: a case study in collaboration. In: Vollmar J., and Hothorn L.A. (Eds). Biometrics in the pharmaceutical industry vol. 7 (1997), Gustav Fischer, Stuttgart, Germany 3-26
16. Le Merre C., Bengtsson T., Carlholm M., and Ostinelli J. Effect on lung function and inflammatory markers of single doses of inhaled budesonide in asthmatics. Am J Respir Crit Care Med 155 (1997) A352
17. Rohatagi S., Appajosyula S., Derendorf H., et al. Risk-benefit value of inhaled glucocorticosids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44 (2004) 37-47
18. Palmqvist M., Persson G., Lazer L., et al. Inhaled dry powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10 (1997) 2484-2489
19. Fieller E.C. A fundamental formula in the statistics of biological assay, and some applications. Q J Pharm 17 (1944) 117-123
20. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002 [published correction appears in J Allergy Clin Immunol. 2003;111:466]. J Allergy Clin Immunol 110 Suppl 5 (2002) S141-S219
21. Dolovich M.B., Ahrens R.C., Hess D.R., et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127 (2005) 335-371
22. Newman S.P. Principles of metered-dose inhaler design. Respir Care 50 (2005) 1177-1188
23. Leach C.L. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 50 (2005) 1201-1206
24. Senn S.J. Statistical issues in short-term trials in asthma. Drug Inf J 27 (1993) 779-791